Accessibility navigation


Decision-theoretic designs for phase II clinical trials allowing for competing studies

Stallard, N. (2003) Decision-theoretic designs for phase II clinical trials allowing for competing studies. Biometrics, 59 (2). pp. 402-409. ISSN 0006-341X

Full text not archived in this repository.

To link to this article DOI: 10.1111/1541-0420.00047

Abstract/Summary

This article describes an approach to optimal design of phase II clinical trials using Bayesian decision theory. The method proposed extends that suggested by Stallard (1998, Biometrics54, 279–294) in which designs were obtained to maximize a gain function including the cost of drug development and the benefit from a successful therapy. Here, the approach is extended by the consideration of other potential therapies, the development of which is competing for the same limited resources. The resulting optimal designs are shown to have frequentist properties much more similar to those traditionally used in phase II trials.

Item Type:Article
Refereed:Yes
Divisions:Faculty of Science > School of Mathematical and Physical Sciences > Department of Mathematics and Statistics > Applied Statistics
ID Code:9455
Uncontrolled Keywords:Backward induction, Cost-benefit analysis, Optimal stopping, Sequential procedure

Centaur Editors: Update this record

Page navigation